
Sign up to save your podcasts
Or


Moderna pops on “robust” early results on its Covid-19 vaccine candidate, but will it pass the next big test? UnitedHealth’s 2nd-quarter profits are much higher than expected, but executives are quick to point out why investors shouldn’t get too excited. Emily Flippen analyzes those stories and shares why she’ll be watching Chinese search giant Baidu this earnings season.
By The Motley Fool4.7
16041,604 ratings
Moderna pops on “robust” early results on its Covid-19 vaccine candidate, but will it pass the next big test? UnitedHealth’s 2nd-quarter profits are much higher than expected, but executives are quick to point out why investors shouldn’t get too excited. Emily Flippen analyzes those stories and shares why she’ll be watching Chinese search giant Baidu this earnings season.

3,230 Listeners

1,498 Listeners

806 Listeners

940 Listeners

532 Listeners

1,186 Listeners

2,190 Listeners

825 Listeners

1,430 Listeners

1,044 Listeners

9,715 Listeners

194 Listeners

830 Listeners

83 Listeners

585 Listeners

1,035 Listeners

51 Listeners